CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2018-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2659 |
| _version_ | 1797856819632144384 |
|---|---|
| author | R. Rahmatini G. Aliska M. Syafri A. Achyar |
| author_facet | R. Rahmatini G. Aliska M. Syafri A. Achyar |
| author_sort | R. Rahmatini |
| collection | DOAJ |
| description | Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of clopidogrel on platelet reactivity was identified through examination of PRU values using VerifyNow® with a cut-off point of 208. From the PRU values, it can be classified whether patients were resistant or responsive.Results. This study shows that 30 patients with ACS who received clopidogrel, 24 patients (80%) were male and 6 female patients (20%). Hypertension was the greatest risk factor for the coronary arterial disease. A total of 11 patients (36,77%) were resistant and 19 patients (63,33%) were responsive to clopidogrel. About 46,67% patients were extensive metabolizers. PRU of these patients were lower than intermediate and poor metabolizers.Conclusion. ACS patients with functional loss of CYP2C19 activity have lower platelet activity when treated with clopidogrel. Routine CYP2C19 and PRU testing may be warranted. Further research is needed with a larger number of patients to investigate the pharmacogenetic profile of CYP2C19 and the cause of clopidogrel resistance in Minang patients. |
| first_indexed | 2024-04-09T20:47:53Z |
| format | Article |
| id | doaj.art-7d8b678ca97f425c8bb5a5cf2c4e05b3 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:47:53Z |
| publishDate | 2018-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-7d8b678ca97f425c8bb5a5cf2c4e05b32023-03-29T21:23:30Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202018-04-0103495310.15829/1560-4071-2018-3-49-532332CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMSR. Rahmatini0G. Aliska1M. Syafri2A. Achyar3Andalas University.Andalas University.Dr. M. Djamil Hospital ; Andalas University.Andalas University.Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of clopidogrel on platelet reactivity was identified through examination of PRU values using VerifyNow® with a cut-off point of 208. From the PRU values, it can be classified whether patients were resistant or responsive.Results. This study shows that 30 patients with ACS who received clopidogrel, 24 patients (80%) were male and 6 female patients (20%). Hypertension was the greatest risk factor for the coronary arterial disease. A total of 11 patients (36,77%) were resistant and 19 patients (63,33%) were responsive to clopidogrel. About 46,67% patients were extensive metabolizers. PRU of these patients were lower than intermediate and poor metabolizers.Conclusion. ACS patients with functional loss of CYP2C19 activity have lower platelet activity when treated with clopidogrel. Routine CYP2C19 and PRU testing may be warranted. Further research is needed with a larger number of patients to investigate the pharmacogenetic profile of CYP2C19 and the cause of clopidogrel resistance in Minang patients.https://russjcardiol.elpub.ru/jour/article/view/2659acute coronary syndromeclopidogrelcyp2c19 polymorphismpru |
| spellingShingle | R. Rahmatini G. Aliska M. Syafri A. Achyar CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS Российский кардиологический журнал acute coronary syndrome clopidogrel cyp2c19 polymorphism pru |
| title | CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS |
| title_full | CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS |
| title_fullStr | CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS |
| title_full_unstemmed | CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS |
| title_short | CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS |
| title_sort | clopidogrel response in acute coronary syndrome patients with cyp2y12 2 and cyp2y12 3 polymorphisms |
| topic | acute coronary syndrome clopidogrel cyp2c19 polymorphism pru |
| url | https://russjcardiol.elpub.ru/jour/article/view/2659 |
| work_keys_str_mv | AT rrahmatini clopidogrelresponseinacutecoronarysyndromepatientswithcyp2y122andcyp2y123polymorphisms AT galiska clopidogrelresponseinacutecoronarysyndromepatientswithcyp2y122andcyp2y123polymorphisms AT msyafri clopidogrelresponseinacutecoronarysyndromepatientswithcyp2y122andcyp2y123polymorphisms AT aachyar clopidogrelresponseinacutecoronarysyndromepatientswithcyp2y122andcyp2y123polymorphisms |